^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anastrozole

    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    11d
    TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Jun 2025
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane
    14d
    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (clinicaltrials.gov)
    P3, N=1156, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    tamoxifen • letrozole • anastrozole • exemestane
    21d
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Oana Danciu | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    21d
    ELEGANT: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (clinicaltrials.gov)
    P3, N=4220, Recruiting, Stemline Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    25d
    A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial. (PubMed, Ann Oncol)
    With longer follow-up and most patients off ribociclib, NATALEE continues to demonstrate iDFS benefit with ribociclib plus NSAI over NSAI alone in the overall population and across key subgroups. Observed adverse events remained stable.
    P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    1m
    AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=376, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    1m
    Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov)
    P4, N=137, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2030 --> Feb 2028 | Trial primary completion date: Feb 2030 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • goserelin acetate
    1m
    Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov)
    P2, N=48, Recruiting, Ruth O'Regan | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    1m
    Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial. (PubMed, Chin Med J (Engl))
    Abemaciclib plus ET led to improvements in PFS and ORR, a manageable safety profile, and sustained HRQoL, providing clinical benefit without a high toxicity burden or reduced quality of life.
    P3 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole
    1m
    EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, AstraZeneca | Trial completion date: Jul 2030 --> Oct 2030
    Trial completion date
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • camizestrant (AZD9833) • saruparib (AZD5305)
    1m
    CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov)
    P=N/A, N=232, Completed, University of Colorado, Denver | Active, not recruiting --> Completed | N=379 --> 232
    Trial completion • Enrollment change
    |
    anastrozole
    1m
    MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov)
    P3, N=493, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Verzenio (abemaciclib) • letrozole • anastrozole
    2ms
    EMERALD: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3; Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Guardant360® CDx
    |
    fulvestrant • letrozole • anastrozole • exemestane • Orserdu (elacestrant)
    2ms
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov)
    P3, N=312, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation • HER-2 negative + HR positive + ESR1 mutation
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
    2ms
    RaPhLRR: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, Oana Danciu | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    2ms
    A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone (clinicaltrials.gov)
    P2, N=34, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Sep 2024 | Trial primary completion date: Apr 2025 --> Sep 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Pan tumor
    |
    PGR expression
    |
    anastrozole • Apristor (onapristone XR)
    2ms
    Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=60, Suspended, University of Washington | Recruiting --> Suspended
    Trial suspension • Metastases
    |
    tamoxifen • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane
    2ms
    A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (clinicaltrials.gov)
    P1/2, N=402, Active, not recruiting, Sihuan Pharmaceutical Holdings Group Ltd. | Recruiting --> Active, not recruiting | N=300 --> 402 | Trial completion date: Dec 2022 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • letrozole • anastrozole • bireociclib (XZP 3287)
    2ms
    AMBRE: Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (clinicaltrials.gov)
    P3, N=180, Active, not recruiting, UNICANCER | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Jun 2025
    Enrollment closed • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    paclitaxel • capecitabine • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole
    2ms
    Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications. (PubMed, Molecules)
    These findings, supported by molecular docking scores and MM-PBSA binding energies, advocate for their potential superior inhibitory capability against the AKT1 enzyme. Nevertheless, it is crucial to validate these computational predictions through in vitro and in vivo studies to thoroughly evaluate the therapeutic potential and viability of these compounds for AKT1-targeted breast cancer treatment.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1)
    |
    epirubicin • anastrozole
    2ms
    PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Medical College of Wisconsin | Trial completion date: Jul 2024 --> Mar 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2ms
    Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study. (PubMed, Ther Adv Med Oncol)
    The recommended phase III dose of dalpiciclib was 150 mg. ClinicalTrials.gov identifier: NCT03481998.
    P1 data • Journal • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    fulvestrant • letrozole • anastrozole • AiRuiKang (dalpiciclib)
    3ms
    PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov)
    P1, N=193, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting | N=400 --> 193
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation • PIK3CA H1047R
    |
    paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • imlunestrant (LY3484356) • LOXO-783
    3ms
    TACTIVE-N: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (clinicaltrials.gov)
    P2, N=152, Completed, Arvinas Inc. | Active, not recruiting --> Completed
    Trial completion • Surgery
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    anastrozole • vepdegestrant (ARV-471)
    3ms
    Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov)
    P2, N=201, Completed, Priscilla McAuliffe | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    tamoxifen • fulvestrant • anastrozole
    3ms
    EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Aug 2024
    Enrollment open • Trial initiation date • Metastases
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • camizestrant (AZD9833) • saruparib (AZD5305)
    3ms
    POWER: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Shayna Showalter, MD | Trial primary completion date: Mar 2024 --> Jun 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    tamoxifen • letrozole • anastrozole • exemestane
    3ms
    A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial. (PubMed, Cancer Control)
    Clinical and pathological responses will be measured overall and in the luminal tumor A subgroup. Toxicity, health-related quality of life, and circulating biomarkers predicting early NET response will also be evaluated.
    Clinical protocol • P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    anastrozole
    3ms
    Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer. (PubMed, J Womens Health (Larchmt))
    Beneficiaries who initiated tamoxifen, anastrozole, letrozole, or exemestane within 3 months after cancer diagnosis were defined as initiators (n = 24,289), and those who never initiated these treatments were noninitiators (n = 8,899). ET initiation and adherence was associated with reduced risk of all-cause (adjusted HR = 0.62, 0.59-0.66; HR = 0.55, 0.53-0.59; respectively) and breast cancer related (adjusted HR = 0.57, 0.50-0.64; HR = 0.41, 0.36-0.47; respectively) mortality compared with noninitiators. Women with early-stage breast cancer who initiate ET and are adherent to treatment may achieve survival benefits compared with noninitiators.
    Journal
    |
    ER (Estrogen receptor)
    |
    tamoxifen • letrozole • anastrozole • exemestane
    3ms
    OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov)
    P3, N=250, Recruiting, Tolmar Inc. | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)
    4ms
    GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, University of Maryland, Baltimore | Trial primary completion date: Mar 2024 --> Jul 2024
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    letrozole • anastrozole
    4ms
    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Dec 2025
    Trial completion date • Combination therapy • Metastases
    |
    Herceptin (trastuzumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • denifanstat (TVB-2640)
    4ms
    Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov)
    P1/2, N=44, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • anastrozole
    4ms
    RARE CASE OF THERAPY-RELATED ACUTE MYELOID LEUKEMIA FROM BREAST CARCINOMA MANAGEMENT WITH PALBOCICLIB (CHEST 2024)
    She was subsequently started on Alpelisib with Fulvestrant, however, Alpelisib was discontinued due to hyperglycemia. Arimidex was also started but was eventually discontinued due to worsening lung nodules on PET/CT...She was started on Venetoclax and Azacitidine, her pancytopenia improved, however, has overall poor prognosis...Gemcitabine's anti-AML activity and short-term exposure for other treatments make them unlikely to trigger t-AML. This report encourages analysis of long-term genotoxic side-effects of Palbociclib in breast cancer management and bone marrow biopsy is crucial when prolonged pancytopenia exists post treatment.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    Venclexta (venetoclax) • Ibrance (palbociclib) • gemcitabine • Piqray (alpelisib) • azacitidine • fulvestrant • anastrozole
    4ms
    Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score (clinicaltrials.gov)
    P2; Trial completion date: Jan 2030 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • fulvestrant • anastrozole • exemestane • goserelin acetate
    4ms
    Pre-Operative Window of ET to Inform RT Decisions (POWER II) (clinicaltrials.gov)
    P3, N=284, Recruiting, University of Virginia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tamoxifen • letrozole • anastrozole • exemestane
    4ms
    Pre-Operative Window of ET to Inform RT Decisions (POWER II) (clinicaltrials.gov)
    P3, N=284, Not yet recruiting, University of Virginia
    New P3 trial
    |
    tamoxifen • letrozole • anastrozole • exemestane
    4ms
    POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov)
    P2, N=19, Completed, Dartmouth-Hitchcock Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    tamoxifen • letrozole • anastrozole • exemestane
    4ms
    Comparing efficacy and safety of dalpiciclib in combination with neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in HR-strong-positive and HER2-negative breast cancer patients: a multicenter, open, prospective Phase II study (ChiCTR2400080576)
    P2, N=112, Recruiting, Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • AiRuiKang (dalpiciclib) • goserelin acetate • leuprolide acetate for depot suspension
    4ms
    Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    tamoxifen • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane
    4ms
    A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer (clinicaltrials.gov)
    P=N/A, N=5087, Active, not recruiting, Pfizer
    New trial
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • exemestane
    4ms
    ELEGANT: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (clinicaltrials.gov)
    P3, N=4220, Not yet recruiting, Stemline Therapeutics, Inc.
    New P3 trial
    |
    tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)